Emerging pharmacotherapy for inflammatory bowel diseases. (April 2022)

• Record Type: Journal Article
• Authors: Luo, Hua; Cao, Guiqing; Luo, Chun; Tan, Dechao; Vong, Chi Teng; Xu, Yinyue; Wang, Sicen; Lu, Haitao; Wang, Yitao; Jing, Wanghui
• Is Part Of: Pharmacological research. Volume 178(2022)
• Publication Date: 2022-04
• Subjects: AIEC Adherent-invasive E. coli -- ATP Adenosine triphosphate -- CAM6 Cell adhesion molecule 6 -- CD Crohn's disease -- C. difficile Clostridium difficile -- CRP C-reactive protein -- DSS Dextran sulfate sodium -- E. fecalis, Enterococcus fecalis -- E. coli, Escherichia coli -- FMT Fecal microbiota transplantation -- Foxp3 Forkhead box P3 -- IBD Inflammatory bowel disease -- IFN-γ Interferon-γ -- IL-6 Interleukin 6 -- IL-10 Interleukin 10 -- IL-17 Interleukin 17 -- IL-23 Interleukin 23 -- iTreg Induced regulatory T cells -- JAMs Junctional adhesion molecules -- MAP Mycobacterium avium subspecies paratuberculosis -- MAPK Mitogen-activated protein kinase -- MHC Major histocompatibility complex -- MMP-3 Matrix metalloproteinase 3 -- MPO Myeloperoxidase -- MUC2 Mucus 2 -- MUC3 Mucus 3 -- MUC19 Mucus 19 -- Muc2-/- Muc2 knockout mice -- MyD88 Myeloid differentiation factor 88 -- NLRP3 NOD-like receptor protein 3 -- NOXs NADPH oxidases -- nTreg Natural regulatory T cells -- PDE 4 Phosphodiesterase 4 -- P-gp P-glycoprotein -- QrLx Qingre Zaoshi Liangxue decoction -- RORγt Related orphan receptor gamma-t -- ROS Reactive oxygen species -- STAT3 Signal transducer and activator of transcription 3 -- TCR T cell receptor -- TGF-β Transforming growth factor-β -- Th T-helper -- TIMP-1 Tissue inhibitor of metalloproteinase 1 -- TLR4 Toll like receptor 4 -- TNBS 2, 4, 6-trinitrobenzene sulfonic acid -- TNF-α Tumor necrosis factor-alpha -- Treg Regulatory T cell -- TwHF Tripterygium wilfordii Hook F -- TWP Tripterygium wilfordii polycoride -- UC Ulcerative colitis -- VN Vagus nerve -- YNBY Yunnan Baiyao -- VNS VN stimulation; IBD -- Molecular pathogenesis -- Therapeutic targets -- Emerging pharmacotherapy; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2022.106146
• Languages: English
• ISSNs: 1043-6618

Abstract

Abstract: Inflammatory bowel disease (IBD) refers to a gamut of disorders that are characterized by chronic intestinal inflammation, including ulcerative colitis (UC) and Crohn's disease (CD), which often leads to mucosal ulceration and progressive loss of intestinal function. The etiopathogenesis of IBD has not been completely clarified, although multiple factors involving genetic modifications, host immune dysfunction, intestinal dysbiosis and environmental effects have been implicated. Currently, pharmacotherapies including both non-targeted and targeted biological agents are widely used for the clinical treatment of IBD. In addition, novel therapeutic approaches that target the intestinal microorganisms, such as fecal microbiota transplantation, antibiotics, probiotics and microbial metabolite inhibitors, are also under development. However, these treatments are either accompanied by side effects or cannot achieve complete clinical remission when used alone. The efficacy and safety of drugs are currently a clinical challenge. Thus, advanced drug delivery systems are needed for targeted delivery of drugs to the inflammatory sites and avoid absorption by healthy tissues. In this review, we have summarized the latest research on the pathogenesis of IBD and the emerging pharmacotherapies, and discussed potential therapeutic targets for innovative therapies. Graphical Abstract: ga1 Highlights: The pathogenesis of IBD is briefly reviewed from a therapeutic perspective. Therapeutic targets are specifically summarized to highlight the therapeutic progression against the IBD. Therapeutic targets based emerging pharmacotherapies are intensively analyzed to improve future management of IBD.